Skip to content

Combinational Cell Therapy using Natural Killer Cells and Erbitux in Patients with Advanced Gastric Adenocarcinoma

Combinational Cell Therapy using Natural Killer Cells and Erbitux in Patients with Advanced Gastric Adenocarcinoma

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140818018842N36
Enrollment
3
Registered
2023-12-09
Start date
2023-12-22
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Adenocarcinoma. C16. 9 Malignant neoplasm: Stomach, unspecified

Interventions

Intervention 1: Intervention group: Intravenous injection of Erbitux according to the standard protocol and the number of 7x10^5 NK cells in 3 periods with an interval of 5 days to 3 patients with adv

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Months

Inclusion criteria

Inclusion criteria: Age between 20 and 60 years- Histologically confirmed adenocarcinoma of the stomach- Patients who have relapsed at least once after gastrectomy and did not respond to chemotherapy.- Patients receiving the same chemotherapy regimen.- Patients with the same tumor size.- Diffuse form of histopathology.- Eastern Cooperative Oncology Group (ECOG) performance status<2- Life expectancy of at least 3 months- Absence of heart problems- Proper functioning of vital organs:leukocyte count =3000/mm3neutrophil count =1500/mm3platelet count =100,000/mm3hemoglobin =9.0 g/dLserum aspartate aminotransferase (AST) =100 IU/Lalanine aminotransferase (ALT) =100 IU/Lserum total bilirubin =2 mg/dLserum creatinine =1.5 mg/dLblood urea =25 mg/dL

Exclusion criteria

Exclusion criteria: - Positive test for HIV, HTLV-1, syphilis, hepatitis B and C infections- Severe active infection- Serious complications such as diabetes mellitus, unstable angina, or myocardial infarction within 3 months- Pregnancy or lactation period- History of autoimmune diseases and hypersensitivity- History of receiving any type of cell therapy in the last 6 months

Design outcomes

Primary

MeasureTime frame
Checking the safety and toxicity of the injected cells. Timepoint: 28 days. Method of measurement: Any side effects related to cell injection will be checked and recorded during the injection and up to 28 days after the injection.If a complication is seen during or after the infusion, the following actions will be taken based on the CTCAE guideline:In grade 1, only the infusion is stopped.In grades 2 and 3, the infusion is stopped along with anti-allergic treatments, including corticosteroids and antihistamines.In grade 4, in addition to the above, resuscitation measures and care in the ICU department are also recommended.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Javad Verdi

Tehran University of Medical Sciences

javadverdi2019@gmail.com+98 21 4305 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026